Matthew Barcus

Stock Analyst at Chardan Capital

(2.44)
# 2,548
Out of 5,044 analysts
21
Total ratings
25%
Success rate
26.4%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Matthew Barcus

Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12$10
Current: $3.77
Upside: +165.25%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45$27
Current: $70.00
Upside: -61.43%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.82
Upside: +753.66%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21$32
Current: $21.98
Upside: +45.59%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $0.58
Upside: +37,635.85%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $4.24
Upside: +112.26%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9$8
Current: $16.39
Upside: -51.19%